Abstract
Transient Receptor Potential Vanilloid 1 (TRPV1) is a Ca2+ permeant non-selective cation channel expressed in a subpopulation of primary afferent neurons. TRPV1 is activated by physical and chemical stimuli. It is critical for the detection of nociceptive and thermal inflammatory pain as revealed by the deletion of the TRPV1 gene. TRPV1 is distributed in the peripheral and central terminals of the sensory neurons and plays a role in initiating action potentials at the nerve terminals and modulating neurotransmitter release at the first sensory synapse, respectively. Distribution of TRPV1 in the nerve terminals innervating blood vessels and in parts of the CNS that are not subjected to temperature range that is required to activate TRPV1 suggests a role beyond a noxious thermal sensor. Presently, TRPV1 is being considered as a target for analgesics through evaluation of different antagonists. Here, we will discuss the distribution and the functions of TRPV1, potential use of its agonists and antagonists as analgesics and highlight the functions that are not related to nociceptive transmission that might lead to adverse effects.
Keywords: TRPV1, nociceptors, protein kinases, inflammatory mediators, pain, nociceptive ion channels
Current Neuropharmacology
Title: TRPV1: A Target for Next Generation Analgesics
Volume: 6 Issue: 2
Author(s): Louis S. Premkumar and Parul Sikand
Affiliation:
Keywords: TRPV1, nociceptors, protein kinases, inflammatory mediators, pain, nociceptive ion channels
Abstract: Transient Receptor Potential Vanilloid 1 (TRPV1) is a Ca2+ permeant non-selective cation channel expressed in a subpopulation of primary afferent neurons. TRPV1 is activated by physical and chemical stimuli. It is critical for the detection of nociceptive and thermal inflammatory pain as revealed by the deletion of the TRPV1 gene. TRPV1 is distributed in the peripheral and central terminals of the sensory neurons and plays a role in initiating action potentials at the nerve terminals and modulating neurotransmitter release at the first sensory synapse, respectively. Distribution of TRPV1 in the nerve terminals innervating blood vessels and in parts of the CNS that are not subjected to temperature range that is required to activate TRPV1 suggests a role beyond a noxious thermal sensor. Presently, TRPV1 is being considered as a target for analgesics through evaluation of different antagonists. Here, we will discuss the distribution and the functions of TRPV1, potential use of its agonists and antagonists as analgesics and highlight the functions that are not related to nociceptive transmission that might lead to adverse effects.
Export Options
About this article
Cite this article as:
Premkumar S. Louis and Sikand Parul, TRPV1: A Target for Next Generation Analgesics, Current Neuropharmacology 2008; 6 (2) . https://dx.doi.org/10.2174/157015908784533888
DOI https://dx.doi.org/10.2174/157015908784533888 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ubiquitin Ligases as Key Elements for the Modulation of the Immune Response: An Insight in the Pathogenesis of Autoimmunity
Current Rheumatology Reviews Ionotropic Glutamate Receptors & CNS Disorders
CNS & Neurological Disorders - Drug Targets Identification of Potential MEK1 Inhibitors by Pharmacophore-based Virtual Screening and MD Simulations
Letters in Drug Design & Discovery Perspectives in Medicinal Chemistry:
Current Topics in Medicinal Chemistry Human Mesotrypsin Defies Natural Trypsin Inhibitors: From Passive Resistance to Active Destruction.
Protein & Peptide Letters Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis
Current Drug Targets Inflammatory and Cell Death Pathways in Brain and Peripheral Blood in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Bilateral Interrelationship of Diabetes and Periodontium
Current Diabetes Reviews Dependence of Cell Survival on Correlative Activities of Xanthine Oxidase and Dihydopyrimidine Dehydrogenase in Human Brain-Derived Cell Culture
Central Nervous System Agents in Medicinal Chemistry A Novel Simultaneous Quantification Method for Escitalopram and Etizolam in Human Plasma Using Liquid Chromatography-ESI-Tandem Mass Spectrophotometry-Application to Pharmacokinetic Study
Current Pharmaceutical Analysis Effects of Thyroid Hormones and their Metabolites on Learning and Memory in Normal and Pathological Conditions
Current Drug Metabolism Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Pharmacological Neuroprotection after Perinatal Hypoxic-Ischemic Brain Injury
Current Neuropharmacology A Review on Metal Nanoparticles from Medicinal Plants: Synthesis, Characterization and Applications
Nanoscience & Nanotechnology-Asia Attenuating Effect of Portulaca oleracea Extract on Chronic Constriction Injury Induced Neuropathic Pain in Rats: An Evidence of Anti-oxidative and Anti-inflammatory Effects
CNS & Neurological Disorders - Drug Targets Impact of HLA Haplotype on the Response to Antipsychotic Treatment of Schizophrenia
Current Pharmacogenomics 18F-Labeled 2-Arylquinoline Derivatives for Tau Imaging: Chemical, Radiochemical, Biological and Clinical Features
Current Alzheimer Research The Neuroprotective Role of PEDF: Implication for the Therapy of Neurological Disorders
Current Molecular Medicine Vaccine Therapy for Hepatitis B Virus Carrier
Current Drug Targets - Infectious Disorders The AKT Axis as a Therapeutic Target in Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets